Who currently markets prednisolone sodium phosphate (and who owns the brand) in 2025?
I can’t determine the 2025 “current marketing owner” from the information provided. “Prednisolone sodium phosphate” is a generic name used in multiple branded products across different countries, and the marketing/holding entity can vary by territory, dosage form (tablet, solution, injection), and regulator (e.g., FDA in the US vs. EMA/UK MHRA vs. other national agencies).
To identify the correct 2025 marketing owner, you’ll need to specify at least one of the following:
- Country (and whether you mean US, UK, EU, Canada, etc.)
- Dosage form (oral liquid/tablet vs. injection)
- Strength (e.g., mg/mL, mg/tablet) and pack size, if known
- The brand name you’re looking at (if it’s not just “prednisolone sodium phosphate”)
If you share the country and dosage form (or the product/brand name), I can narrow it to the specific marketing authorization holder/holder of record for 2025.
Why does the “marketing owner” change?
Marketing ownership can change due to:
- Product transfers (a manufacturer or license holder sells rights to another company)
- Marketing authorization changes (new holder assigned by the regulator)
- Different holders for different presentations (e.g., oral vs. injectable)
- Ongoing label/MAH updates after mergers or restructurings
What sources typically list the 2025 marketing owner?
In most jurisdictions, the marketing owner is taken from the regulator’s label/marketing authorization record, such as:
- FDA (US): the “labeler” and application/holder info on the drug label database
- EMA/UK MHRA (EU/UK): marketing authorization holder in the product record
- Other national agencies: MAH/permit holder in their registers
Quick next step
Tell me the country and dosage form (for example, “US injectable” or “UK oral solution”), or paste the brand name from the package/label. Then I can identify the current 2025 marketing owner for that specific product.